Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the wnt/beta-catenin signaling pathway.
(2013) In PLoS ONE 8(11).- Abstract
- Osteoblastoma is a bone forming tumor with histological features highly similar to osteoid osteoma; the discrimination between the tumor types is based on size and growth pattern. The vast majority of osteoblastomas are benign but there is a group of so-called aggressive osteoblastomas that can be diagnostically challenging at the histopathological level. The genetic aberrations required for osteoblastoma development are not known and no genetic difference between conventional and aggressive osteoblastoma has been reported. In order to identify recurrent genomic aberrations of importance for tumor development we applied cytogenetic and/or SNP array analyses on nine conventional and two aggressive osteoblastomas. The conventional... (More)
- Osteoblastoma is a bone forming tumor with histological features highly similar to osteoid osteoma; the discrimination between the tumor types is based on size and growth pattern. The vast majority of osteoblastomas are benign but there is a group of so-called aggressive osteoblastomas that can be diagnostically challenging at the histopathological level. The genetic aberrations required for osteoblastoma development are not known and no genetic difference between conventional and aggressive osteoblastoma has been reported. In order to identify recurrent genomic aberrations of importance for tumor development we applied cytogenetic and/or SNP array analyses on nine conventional and two aggressive osteoblastomas. The conventional osteoblastomas showed few or no acquired genetic aberrations while the aggressive tumors displayed heavily rearranged genomes. In one of the aggressive osteoblastomas, three neighboring regions in chromosome band 22q12 were homozygously deleted. Hemizygous deletions of these regions were found in two additional cases, one aggressive and one conventional. In total, 10 genes were recurrently and homozygously lost in osteoblastoma. Four of them are functionally involved in regulating osteogenesis and/or tumorigenesis. MN1 and NF2 have previously been implicated in the development of leukemia and solid tumors, and ZNRF3 and KREMEN1 are inhibitors of the Wnt/beta-catenin signaling pathway. In line with deletions of the latter two genes, high beta-catenin protein expression has previously been reported in osteoblastoma and aberrations affecting the Wnt/beta-catenin pathway have been found in other bone lesions, including osteoma and osteosarcoma. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4179313
- author
- Hansén Nord, Karolin LU ; Nilsson, Jenny LU ; Arbajian, Elsa LU ; Vult von Steyern, Fredrik LU ; Brosjö, Otte ; Cleton-Jansen, Anne-Marie ; Szuhai, Karoly and Hogendoorn, Pancras C W
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- PLoS ONE
- volume
- 8
- issue
- 11
- article number
- e80725
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- wos:000327254700200
- pmid:24236197
- scopus:84893164853
- pmid:24236197
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0080725
- language
- English
- LU publication?
- yes
- id
- 34905b4c-aaff-4fb8-a70a-2b6cae5126e3 (old id 4179313)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24236197?dopt=Abstract
- date added to LUP
- 2016-04-01 14:26:39
- date last changed
- 2022-04-22 03:13:22
@article{34905b4c-aaff-4fb8-a70a-2b6cae5126e3,
abstract = {{Osteoblastoma is a bone forming tumor with histological features highly similar to osteoid osteoma; the discrimination between the tumor types is based on size and growth pattern. The vast majority of osteoblastomas are benign but there is a group of so-called aggressive osteoblastomas that can be diagnostically challenging at the histopathological level. The genetic aberrations required for osteoblastoma development are not known and no genetic difference between conventional and aggressive osteoblastoma has been reported. In order to identify recurrent genomic aberrations of importance for tumor development we applied cytogenetic and/or SNP array analyses on nine conventional and two aggressive osteoblastomas. The conventional osteoblastomas showed few or no acquired genetic aberrations while the aggressive tumors displayed heavily rearranged genomes. In one of the aggressive osteoblastomas, three neighboring regions in chromosome band 22q12 were homozygously deleted. Hemizygous deletions of these regions were found in two additional cases, one aggressive and one conventional. In total, 10 genes were recurrently and homozygously lost in osteoblastoma. Four of them are functionally involved in regulating osteogenesis and/or tumorigenesis. MN1 and NF2 have previously been implicated in the development of leukemia and solid tumors, and ZNRF3 and KREMEN1 are inhibitors of the Wnt/beta-catenin signaling pathway. In line with deletions of the latter two genes, high beta-catenin protein expression has previously been reported in osteoblastoma and aberrations affecting the Wnt/beta-catenin pathway have been found in other bone lesions, including osteoma and osteosarcoma.}},
author = {{Hansén Nord, Karolin and Nilsson, Jenny and Arbajian, Elsa and Vult von Steyern, Fredrik and Brosjö, Otte and Cleton-Jansen, Anne-Marie and Szuhai, Karoly and Hogendoorn, Pancras C W}},
issn = {{1932-6203}},
language = {{eng}},
number = {{11}},
publisher = {{Public Library of Science (PLoS)}},
series = {{PLoS ONE}},
title = {{Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the wnt/beta-catenin signaling pathway.}},
url = {{https://lup.lub.lu.se/search/files/3978213/4431880.pdf}},
doi = {{10.1371/journal.pone.0080725}},
volume = {{8}},
year = {{2013}},
}